MarketFriction

Valiant Laboratories Ltd

NSE VALIANTLAB · BSE 543998 · Pharmaceuticals
₹125.08 -0.91%
NSE close2026-10-01
52 week range49.51 - 132.25
Market cap₹660 Cr.
P/E41.2
IPO 2023 · -11% since ESM Price band 5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales6041311921355847465292115
Expenses614735212835544446538786
Operating Profit-1-6-5-2-71420-1529
OPM %-2.3%-16%-15%-13%-31%1.8%7%5%0.2%-1.7%5%25%
Other Income322332-211101
Interest000000000111
Depreciation001111111233
Profit before tax1-5-3-0-42120-3126
Tax %25%-31%-52%219%21%-44%26%26%25%136%-68%19%
Net Profit1-4-1-1-52120-7221
EPS in Rs0.19-0.64-0.23-0.09-0.870.430.130.340.04-1.300.323.88
Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales334182133237306
Expenses299190138231273
Operating Profit35-8-5633
OPM %11%-4.6%-3.5%2.7%11%
Other Income510523
Interest00023
Depreciation22268
Profit before tax38-1-2125
Tax %24%-142%46%525%
Net Profit290-2-316
EPS in Rs7.130.06-0.41-0.602.94
Dividend Payout %0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%%-11%90%
Compounded Profit Growth%%%12208%
Stock Price CAGR%%%49%
Return on Equity%%-1%-1%
Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital33434354
Reserves68193191257
Borrowings607712246
Other Liabilities522945107
Total Liabilities213343401464
Fixed Assets485048227
CWIP1431566
Investments3438028
Other Assets130212197202
Total Assets213343401464
Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity5621-10
Cash from Investing Activity-55-144-537
Cash from Financing Activity-1152452
Net Cash Flow-010-7-1
Free Cash Flow18-44-112-45
CFO/OP185%-11%25%-147%
Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9792197144
Inventory Days17221384
Days Payable6256128174
Cash Conversion Cycle52578254
Working Capital Days70106156156
ROCE %-2%-1%1%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%
FIIs8.64%7.08%3.48%1.89%0.00%0.00%0.64%0.63%0.02%0.01%0.20%0.00%
DIIs1.76%0.43%0.00%0.00%0.00%0.00%0.00%0.46%0.00%0.00%0.00%0.00%
Public14.66%17.54%21.58%23.18%25.06%25.06%24.42%23.97%25.05%25.05%24.87%25.06%
No. of Shareholders37,43415,82114,91414,24915,18915,69215,03614,43215,07514,91014,65714,341

Fundamentals

Market Cap₹ 660 Cr.
Current Price₹ 122
Stock P/E41.2
Book Value₹ 57.2
ROCE0.75 %
ROE-1.20 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)90%
Compounded Profit Growth (TTM)12208%
Consolidated figures.
Ownership
Promoter holding74.94% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
PeriodVALIANTLABNifty 50Difference
1 week+1.6%-2.8% +4.3 pts
1 month+36.6%-6.8% +43.4 pts
3 months+92.4%-7.6% +100.0 pts
6 months+142.3%+0.4% +141.9 pts
1 year+46.5%-9.9% +56.5 pts
2 years+5.4%-13.6% +18.9 pts

Red flags

lookRegulator order or action Regulator order or action 2026-05-30: Valiant Laboratories Limited has informed the Exchange about Action(s) taken or orders passed by the GST Authority
lookOn NSE surveillance On NSE surveillance: ESM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹115 Cr +144.7% vs Jun 2025. Net profit ₹21 Cr +950.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2025-07-18Rights 1:4 @ Premium Rs 65/-
DateTypeWhat it says
2026-09-29Shareholder meetingVoting results.
2026-09-28Shareholder meetingProceedings of Annual General Meeting held on September 28, 2026
2026-09-17General UpdatesInvestment in AMPYR Renewable Energy Resources Twelve A Private Limited
2026-09-03Credit RatingCredit Rating
2026-09-03General UpdatesLetter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015.
2026-09-03Shareholder meetingNotice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26
2026-08-10Monitoring Agency ReportMonitoring Agency Report for quarter ended June 30, 2026
2026-08-10Address ChangeChange in Corporate Office of the company.
2026-08-10Address ChangeChange in Registered Office of the company.
2026-08-10General UpdatesAdditional investment in Valiant Advanced Sciences Private Limited ("VASPL") up to an amount not exceeding Rs. 60 Crore, by way of subscription to 1% ...
2026-08-10Director changeChange in Director(s) of the company.
2026-08-10Board meeting outcomeValiant Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-06-25Reply to Clarification- FinaThe Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (L...
2026-06-01Reply to Clarification- FinaThe Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (L...
2026-05-30Regulatory actionAction(s) taken or orders passed by the GST Authority
2026-05-26Disclosure under SEBI TakeovSantosh Vora has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu...
2026-05-26Disclosure under SEBI TakeovSantosh Vora has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu...
2026-05-25Clarification - Financial ReThe Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (L...
2026-05-20Disclosure under SEBI TakeovValiant Organics Limited has Submitted to the Exchange a copy of Disclosure under Regulation 10 (5) of the Securities and Exchange Board of India (Sub...
2026-05-19UpdatesIntimation Recieved Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011.
2026-05-16Press ReleaseA press release dated May 16, 2026, titled "Valiant Laboratories Limited announces evaluation of Restructuring options.".
2026-05-14Monitoring Agency ReportMonitoring Agency Report for the quarter ended March 31, 2026.
2026-05-14Board meeting outcomeValiant Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-14Board meeting outcomeOutcome of Board Meeting held on May 14, 2026 w.r.t appointment of Cost and Internal Auditor.
2026-05-14Board meeting outcomeValiant Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03